These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12654655)

  • 21. Mutations of the rpoB gene in rifampicin-resistant Streptococcus pneumoniae in Taiwan.
    Chen JY; Fung CP; Chang FY; Huang LY; Chang JC; Siu LK
    J Antimicrob Chemother; 2004 Feb; 53(2):375-8. PubMed ID: 14729734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypermutability in clinical isolates of Klebsiella pneumoniae is uncommon and is unrelated to ciprofloxacin resistance.
    Aathithan S; French GL
    Int J Antimicrob Agents; 2010 Sep; 36(3):239-42. PubMed ID: 20541915
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of drug sensitivity and genotypes of clinically isolated strains of levofloxacin-resistant Streptococcus pneumoniae obtained from Okinawa Island, the Japanese main island and Hong Kong.
    Sunagawa S; Fujita J; Higa F; Tateyama M; Haranaga S; Nakasone I; Yamane N; Uno T
    J Antibiot (Tokyo); 2011 Aug; 64(8):539-45. PubMed ID: 21587266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae.
    Zeller V; Janoir C; Kitzis MD; Gutmann L; Moreau NJ
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1973-8. PubMed ID: 9303396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
    Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
    J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae.
    Davies TA; Pankuch GA; Dewasse BE; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1999 May; 43(5):1177-82. PubMed ID: 10223932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae.
    Broskey J; Coleman K; Gwynn MN; McCloskey L; Traini C; Voelker L; Warren R
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():95-9. PubMed ID: 10824039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis.
    Janoir C; Podglajen I; Kitzis MD; Poyart C; Gutmann L
    J Infect Dis; 1999 Aug; 180(2):555-8. PubMed ID: 10395882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipneumococcal activity of DK-507k, a new quinolone, compared with the activities of 10 other agents.
    Browne FA; Bozdogan B; Clark C; Kelly LM; Ednie L; Kosowska K; Dewasse B; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3815-24. PubMed ID: 14638489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF; Zhao CJ; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG; Roberts D; Waltky A; Laing N; Nichol K; Smith H; Noreddin A; Bellyou T; Hoban DJ
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid screening of fluoroquinolone resistance determinants in Streptococcus pneumoniae by PCR-restriction fragment length polymorphism and single-strand conformational polymorphism.
    Ip M; Chau SS; Chi F; Qi A; Lai RW
    J Clin Microbiol; 2006 Mar; 44(3):970-5. PubMed ID: 16517885
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1998 Nov; 42(11):2810-6. PubMed ID: 9797208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.